Drug Profile

Research programme: autism spectrum disorder therapeutics - KoBioLabs

Alternative Names: KBLP-010

Latest Information Update: 18 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator KoBioLabs
Class Bacteria; Behavioural disorder therapies
Mechanism of Action Bacteria replacements; Microbiome modulators; Tryptophan hydroxylase modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

18 Jun 2025 Research programme: autism spectrum disorder therapeutics - KoBioLabs is still in preclinical trials for Pervasive child development disorders in South Korea (KoBioLabs pipeline, June 2025)
28 Apr 2023 No recent reports of development identified for preclinical development in Autism spectrum disorder in South Korea
01 Sep 2021 KoBioLabs plans a phase I trial for Autism spectrum disorder in 2021

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com